作者: Tian, Haoran ; Zhao, Quanzhi ; Zhang, Jing ; Liu, Ye ; Zhao, Yafan ; Zhao, Shuaibing ; Wang, Rongxia ; Gao, Boyan ; Peng, Ting ; Li, Jialu ; Li, Fei ; Teotia, Sachin ; Cheng, Yuan

Fatty acids play a putative role as second messengers of phytohormones and regulate the rice grain weight. However, the inner mechanism is still unclear and needs to be further studied. In this study, we identified that oleic acid (C18:1) negatively correlates while linoleic acid (C18:2) positively correlates with rice grain weight. Field trials showed that 1000-grain weight was significantly reduced when treated with the fatty acid synthesis inhibitor, Firsocostat S enantiomer (FSE), at the heading and flowering stages. RNA-seq analysis revealed that FSE affects grain weight by modulating processes, such as glycolysis, sucrose metabolism, and hormone signaling. Notably, FSE inhibited the expression of OsLIN6, which is responsible for transporting C18:1 to the phosphatidylcholine pool for C18:2 synthesis. Compared with the wild type (WT), the OsLIN6 knockout mutant exhibited a lower grain weight, an increased C18:1 content, and a decreased C18:2 content. Importantly, OsARF12 was shown to bind to the OsLIN6 promoter and activate its expression. In summary, this study highlights the crucial role of the fatty acid synthesis gene, OsLIN6, which was regulated by OsARF12, in rice grain weight determination, thus establishing the molecular link between fatty acid synthesis and auxin signaling.

2024-08-01·Acta Obstetricia et Gynecologica Scandinavica

Antibiotic or gastric acid inhibitor use during pregnancy and postpartum depression: Population‐based cohort study

Article

作者: Brusselaers, Nele ; Fornes, Romina ; Gudnadottir, Unnur ; Kamau, Njeri ; Nguyen, Minh Hanh ; Fransson, Emma ; Bruyndonckx, Robin ; Engstrand, Lars ; Callens, Steven

AbstractIntroductionPostpartum depression is one of the most common non‐obstetric postnatal complications. As the microbiome (and gut–brain axis) as well as inflammation may be involved in the mechanism, we aimed to assess if antibiotic or gastric acid inhibition use during pregnancy affects the risk of postpartum depression (clinical diagnosis and/or antidepressant use up to 1 year after childbirth).Material and MethodsThis population‐based cohort study used first singleton pregnancy resulting in a live birth in Sweden from 2006 to 2016. Women with history of depression were excluded. Multivariable logistic regression models were used to assess the impact of antibiotics and gastric acid inhibitors and other risk factors, presented as odds ratios (ORs) with 95% confidence intervals (CI).ResultsOverall, 29% of all 10 666 women with postpartum depression were exposed to antibiotics and 6.2% to gastric acid inhibitors, compared to, respectively, 21% and 3.2% of 613 205 women without postpartum depression. Antibiotic use during pregnancy was associated with postpartum depression (OR 1.43, 95% CI 1.37–1.49), particularly for quinolones and other antibacterials (including nitroimidazole derivatives). Gastric acid inhibition was associated with an even higher risk than antibiotics (OR 2.04, 95% CI 1.88–2.21). Both antibiotics and gastric acid inhibitors suggested higher risk with increased dose in a dose–response analysis.ConclusionsThe use of antibiotics and gastric acid inhibition drugs during pregnancy appeared to be associated with a higher risk of postpartum depression. However, it is important to consider that other predisposing factors could contribute to this increased risk, even after excluding individuals with a history of depression.

2021-11-01·International Journal of Drug Policy2区 · 医学

Pharmacotherapies for cannabis use disorder: A systematic review and network meta-analysis

2区 · 医学

Review

作者: Tibbo, Philip G ; Bahji, Anees ; Hawken, Emily R ; Meyyappan, Arthi Chinna

OBJECTIVEThis study aimed to determine the efficacy and acceptability of pharmacotherapies for cannabis use disorder (CUD).METHODSWe conducted a systematic review and frequentist network meta-analysis, searching five electronic databases for randomized placebo-controlled trials of individuals diagnosed with CUD receiving pharmacotherapy with or without concomitant psychotherapy. Primary outcomes were the reduction in cannabis use and retention in treatment. Secondary outcomes were adverse events, discontinuation due to adverse events, total abstinence, withdrawal symptoms, cravings, and CUD severity. We applied a frequentist, random-effects Network Meta-Analysis model to pool effect sizes across trials using standardized mean differences (SMD, g) and rate ratios (RR) with their 95% confidence intervals.RESULTSWe identified a total of 24 trials (n=1912, 74.9% male, mean age 30.2 years). Nabilone (d=-4.47 [-8.15; -0.79]), topiramate (d=-3.80 [-7.06; -0.54]), and fatty-acid amyl hydroxylase inhibitors (d=-2.30 [-4.75; 0.15]) reduced cannabis use relative to placebo. Dronabinol improved retention in treatment (RR=1.27 [1.02; 1.57]), while topiramate worsened treatment retention (RR=0.62 [0.42; 0.91]). Gabapentin reduced cannabis cravings (d=-2.42 [-3.53; -1.32], while vilazodone worsened craving severity (d=1.69 [0.71; 2.66]. Buspirone (RR=1.14 [1.00; 1.29]), venlafaxine (RR=1.78 [1.40; 2.26]), and topiramate (RR=9.10 [1.27; 65.11]) caused more adverse events, while topiramate caused more dropouts due to adverse events.CONCLUSIONSBased on this review, some medications appeared to show promise for treating individual aspects of CUD. However, there is a lack of robust evidence to support any particular pharmacological treatment. There is a need for additional studies to expand the evidence base for CUD pharmacotherapy. While medication strategies may become an integral component for CUD treatment one day, psychosocial interventions should remain the first line given the limitations in the available evidence.

100 项与 Fatty acid biosynthesis inhibitors(Arkansas State University) 相关的药物交易

登录后查看更多信息